Czy garcinol może okazać się lekiem epigenetycznym?

Podsumowanie

Substancje kształtujące epigenom stanowią szybko rozwijającą się gałąź nowoczesnej farmakologii. Zastosowanie inhibotorów HAT może okazać się skuteczną formą terapii chorób onkologicznych. Garcinol, który jest naturalnym inhibitorem acetylotransferazy histonowej wykazuje wiele cech, pozwalających zaliczyć go do grona substancji przeciwnowotworowych. Inhibitor ten skutecznie zmniejsza tempo proliferacji komórek nowotworowych, stymuluje ich apoptozę, hamuje migrację i obniża zdolność do angiogenezy. Dodatkowo garcinol uwrażliwia komórki nowotworowe na stosowanie radio- i chemioterapii co podnosi skuteczność stosowanego leczenia i zmniejsza jego skutki uboczne. Obiecujące wyniki badań in vitro oraz in vivo zachęcają do dalszych badań, w tym potwierdzenia jego korzystnego wpływu na hamowanie rozwoju chorób nowotworowych w badaniach klinicznych.

Literatura

ADWAN L.,ZAWIA N.H.2013.Epigenetics: a novel therapeutic approach for the treatment of Alzheimer’s disease. Pharmacol Ther. 139, 1, 41-50.
BLIXT N. C., FAULKNER B. K., ASTLE- FORD K., LELICH R., SCHERING J., ET AL. 2017. Class II and IV HDACs function as inhibitors of osteoclast differentiation. PLoS One. 12, 9, 1371-1392.
BROWN J., BOURKE E., ERIKSSON L., KERIN M. 2016.Targeting cancer using KAT inhibitors to mimic lethal knockouts. Biochem Soc Trans. 44, 4, 979-986.
CHEN H. P., ZHAO Y.T., ZHAO T. C. 2015. Histone Deacetylases and Mechanisms of Reg- ulation of Gene Expression (Histone deacety- lases in cancer). Crit Rev Oncog. 20, 35-47.
COLLINS H. M., ABDELGHANY M. K., MESSMER M., YOU B.,DEEVES S.E., ET AL. 2013. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer. 13, 37-47.
ECKSCHLAGER T., PLCH J., STIBORO- VA M., HRABETA J. 2017. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 7, 1414-1438.
FALAHI F., SGRO A., BLANCAFORT P. 2015. Epigenome Engineering in Cancer: Fai- rytale or a Realistic Path to the Clinic? Front Oncol. 5, 22-31.
GADHIA S., SHRIMP J. H., MEIER J. L., MCGEE J. E., DAHLIN J. L., ET AL. 2017. Histone Acetyltransferase Assays in Drug and Chemical Probe Discovery. Assay Guidance Manual. 1, 1-50.
GAJER J. M., FURDAS S.D., GRUNDER A., GOTHWAL M., HEINICKE U., ET AL. 2015. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. On- cogenesis. 4, 137-146.
GATLA H. R., ZOU Y., UDDIN M. M., VANCUROVA I. 2017. Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells. Oncotarget. 8, 41, 70798-70810.
GLOZAK M. A., SETO E. 2007. Histone deacetylases and cancer oncogene. Oncogene. 26, 5420–5432.
GORDON J. A., STEIN J.L., WESTEN- DORF J. J., VAN WIJNEN A. J. 2015. Chro- matin modifiers and histone modifications in bone formation, regeneration, and therapeutic intervention for bone-related disease. Bone. 81, 739-745.
HAERY L., THOMPSON R. C., GILM- ORE T. D. 2015. Histone acetyltransferases and histone deacetylases in B- and T-cell de- velopment, physiology and malignancy. Genes Cancer. 6, 184-213.
HAN Y., HE X. 2016. Integrating Epigenom- ics into the Understanding of Biomedical In- sight. Bioinform Biol Insights. 10, 267-289.
HEERBOTH S., LAPINSKA K., SNYDER N., LEARY M., ROLLINSON S., ET AL. 2014. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 6, 9-19.
HOU H., ZHENG X., ZHANG H., YUE M., HU Y., ET AL. 2017. Histone Deacety- lase Is Required for GA-Induced Programmed Cell Death in Maize Aleurone Layers. Plant Physiol. 175, 3, 1484–1496.
KHULLAR M., CHEEMA B. S., RAUT S. K. 2017. Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes. 8, 237-250.
KOPYTKO P., BUJAK J., LUBECKA M. 2017. Inhibitory HDAC w terapii chorób no- wotworowych. Nauka, Badania i Doniesienia Naukowe. 1, 278-287.
LI F., SHANMUGAN M. K., SIVEEN K. S., WANG F., ONG T.H., ET AL. 2015. Garcin- ol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. Oncotarget. 7, 5147-5163.
LI F., SHANMUGAN M. K., SIVEEN K. S., WANG F., ONG T.H., ET AL. 2013. Gar- cinol, a polyisoprenylated benzophenone mod- ulates multiple proinflammatory signaling cas- cades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prev Res. 8, 843-54.
OIKE T., OGIWARA H., TORIKAI K., NAKANO T., YOKOTA J., ET AL. 2012. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non- homologous end joining. Int J Radiat Oncol Biol Phys. 84, 3, 815-821.
PARASRAMKA M. A., GUPTA S. V. 2011. Garcinol inhibits cell proliferation and pro- motes apoptosis in pancreatic adenocarcinoma cells. Nutr Cancer. 63, 3, 456-465.
RAGAZZONI Y., DESIDERI M., GABEL- LINI C.,DE LUCA T.,CARRADORI S.,ET AL. 2013.The thiazole derivative CPTH6 im- pairs autophagy. Cell Death Dis. 4, 524-534.
RANJBARNEJAD T., SAIDIJAM M., TA- FAK M. S., POURJAFAR M., TALEBZA- DEH F., ET AL. 2017. Garcinol exhibits anti- proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Hum Exp Toxicol. 36, 7, 692-700.
SAWICKI W., MALEJCZYK J., WRÓ- BLEWSKA M. 2015. Ujarzmianie starzenia: sirtuiny, NFκB, mTOR, GH/IGF1 i ogranic- zenie kaloryczne. Gerontologia Polska. 23, 4, 200-205.
SUN J.,WANG Y.,CUI W.2017.Role of Epi- genetic Histone Modifications in Diabetic Kid- ney Disease Involving Renal Fibrosis. Journal of Diabetes Research. 1, 7242384-7242394.
SUN X. J., MAN N., TAN Y., NIMER S. D., WANG L. 2015. The Role of Histone Acetyl- transferases in Normal and Malignant Hema- topoiesis. Front Oncol. 5, 108-118.
TANG Y., LIN Y. H., NI H. Y., DONG J., YUAN H. J., ET AL. 2017. Inhibiting Histone Deacetylase 2 (HDAC2) Promotes Functional Recovery From Stroke. J Am Heart Assoc. 6, 10, 7236-7263.
TU S. H., CHIOU Y. S., KALYANAM N., HO C. T., CHEN L. C., AT AL. 2017. Gar- cinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model. Food Funct.
WANG Y., TSAI M. L., CHIOU L. Y., HO C.T., PAN M. H. 2015. Antitumor Activity of Garcinol in Human Prostate Cancer Cells and Xenograft Mice. 63, 41, 9047-9052.
WAPENAAR H., DEKKER F. J. 2016. His- tone acetyltransferases: challenges in targeting bi-substrate enzymes. Clin Epigenetics. 8, 59- 69.
WEINHOLD B. 2006. Epigenetics: The Sci- ence of Change. Environ Health Perspect. 114, 3, 160-167.
WILSON C. L., MANN D. A., BORTH- WICK L. A. 2017. Epigenetic reprogram- ming in liver fibrosis and cancer. Drug Deliv. Rev. 121, 124-132.